Shin Park - OliX PharmaceuticalsI Sr Devel
| 226950 Stock | 21,000 100.00 0.48% |
Insider
Shin Park is Sr Devel of OliX PharmaceuticalsInc
| Phone | 82 3 1779 8400 |
| Web | http://www.olixpharma.com |
Shin Park Latest Insider Activity
Tracking and analyzing the buying and selling activities of Shin Park against OliX PharmaceuticalsI stock is an integral part of due diligence when investing in OliX PharmaceuticalsI. Shin Park insider activity provides valuable insight into whether OliX PharmaceuticalsI is net buyers or sellers over its current business cycle. Note, OliX PharmaceuticalsI insiders must abide by specific rules, including filing SEC forms every time they buy or sell OliX PharmaceuticalsI'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Shin Park over six months ago Acquisition by Shin Park of 9000 shares of MagnaChip Semiconductor at 5.56 subject to Rule 16b-3 | ||
Shin Park over a year ago Payment of 1391 shares by Shin Park of MagnaChip Semiconductor subject to Rule 16b-3 | ||
Shin Park over a year ago Acquisition by Shin Park of 37523 shares of MagnaChip Semiconductor subject to Rule 16b-3 |
OliX PharmaceuticalsI Management Efficiency
The company has return on total asset (ROA) of (0.164) % which means that it has lost $0.164 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (76.6277) %, meaning that it generated substantial loss on money invested by shareholders. OliX PharmaceuticalsI's management efficiency ratios could be used to measure how well OliX PharmaceuticalsI manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Hirose Dakashi | Oscotec | N/A | |
| Lopez Michael | Medy Tox | 62 | |
| Jong Won | ABL Bio | N/A | |
| SungHee Son | Oscotec | N/A | |
| Jae Jung | ABL Bio | N/A | |
| SungHo Park | Oscotec | 55 | |
| WooSun Lee | Medy Tox | 46 | |
| Young Cho | LegoChem Biosciences | N/A | |
| Hyang Lee | LegoChem Biosciences | N/A | |
| SoJin Ahn | Oscotec | N/A | |
| JaeSang Lee | Oscotec | N/A | |
| Jong Kim | ABL Bio | N/A | |
| HeeSeok Joo | Medy Tox | 57 | |
| HyunHo Jung | Medy Tox | 61 | |
| Sang Lee | ABL Bio | N/A | |
| You WeonKyoo | ABL Bio | N/A | |
| KiHyuk Yang | Medy Tox | 54 | |
| Jung Kim | ABL Bio | N/A | |
| SeungBum Park | Medy Tox | 54 | |
| SuSung Lee | Oscotec | N/A | |
| Sejin Park | LegoChem Biosciences | 61 | |
Management Performance
| Return On Equity | -76.63 | |||
| Return On Asset | -0.16 |
OliX PharmaceuticalsInc Management Team
Elected by the shareholders, the OliX PharmaceuticalsI's board of directors comprises two types of representatives: OliX PharmaceuticalsI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OliX. The board's role is to monitor OliX PharmaceuticalsI's management team and ensure that shareholders' interests are well served. OliX PharmaceuticalsI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OliX PharmaceuticalsI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| SunWoo Hong, VP Director | ||
| Shin Park, Sr Devel | ||
| DongKi Lee, CEO Director |
OliX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OliX PharmaceuticalsI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -76.63 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (6.56) % | |||
| Current Valuation | 576.53 B | |||
| Shares Outstanding | 6.51 M | |||
| Shares Owned By Insiders | 29.21 % | |||
| Shares Owned By Institutions | 6.02 % | |||
| Price To Sales | 75.58 X | |||
| Revenue | 3.67 B | |||
| Gross Profit | 2.42 B |
Other Information on Investing in OliX Stock
OliX PharmaceuticalsI financial ratios help investors to determine whether OliX Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in OliX with respect to the benefits of owning OliX PharmaceuticalsI security.